EUCTR2006-003391-35-NL
Active, not recruiting
Not Applicable
Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögrens' syndrome
aboratoires THEA0 sitesJuly 5, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- keratoconjunctivitis sicca
- Sponsor
- aboratoires THEA
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male or female aged from 18 to 75 years old.
- •2\.Primary or secondary Sjögren:
- •ØAlready diagnosed by the rheumatologist and the maxillofacial specialist.
- •ØFulfilling the European criteria (Vitali et al 1996\)
- •3\.Severe dry eye syndrome in BOTH EYES defined by:
- •\-Questioning on patient’s feeling: score \= 3\.
- •\-At least two of the following ocular symptoms suggestive of dry eye: burning, stinging, dryness feeling, sandy and/or gritty sensation, light sensitivity, reflex tearing, ocular fatigue, blurred vision (improved by tears substitute).
- •\-Schirmer test \< 5 mm in 5 min OR BUT \< 7 s.
- •\-Keratoconjunctivitis defined by a lissamine green score (Van Bijsterveld score) \= 4
- •Are the trial subjects under 18? no
Exclusion Criteria
- •1\.Dry eye syndrome primarily related to inflammation of ocular surface
- •2\. Contraindications to topic dexamethasone :Glaucoma, IOP steroid responder, Herpes simplex, vaccinia, varicella zoster and most other viral infections of the cornea and conjunctiva, bacterial infections, all lesions with involvement of the corneal epithelium, Tuberculosis, fungal infections, acute purulent infections, which like other diseases caused by micro\-organisms, can be masked or aggravated by the presence of steroids
- •3\.Eyelid dysfunction : Eyelid malposition, Blepharospasm, Facial paralysis, Severe ocular progressive rosacea/ severe blepharitis
- •4\.History WITHIN THE LAST 3 MONTHS before the inclusion visit of : Traumatism, Infection (Viral conjunctivitis / Bacterial conjunctivitis / Staphylococcal blepharitis)
- •5\.Any relevant ocular anomaly interfering with ocular surface: chemical burns, corneal distrophy, orbital radiotherapy, etc…….
- •6\.Known history of ocular allergy.
- •7\. Best corrected far visual acuity (VA) \= 1/10\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Prospective evaluation of efficacy and safety of argon plasma coagulation therapy with submucosal injection prior to ablation in Barrett's esophagusC15.5Lower third of oesophagusDRKS00003369HSK Wiesbaden60
Completed
Not Applicable
Assessment of the Efficacy and Safety of the Use of Perfectha Deep Lidocaine in the Treatment of Nasolabial Folds, Marionette Lines and Temple HollowingR23.4Changes in skin textureDRKS00029739Sinclair Pharmaceuticals LtdEden HouseLakeside70
Completed
Not Applicable
A prospective study of the efficacy and safety of Denosumab for the prevention of osteoporosis in malignant lymphoma patients treated with prednisolone-containing chemotherapyMalignant LymphomaJPRN-UMIN000012362Department of Medical Oncology and Hematology, Sapporo Medical University, School of Medicine30
Recruiting
Not Applicable
A prospective study of the efficacy and safety of preoperative chemotherapy with gemcitabine+nab-paclitaxel therapy for resectable pancreatic body and tail cancer with splenic arteriovenous invasion by image.pancreatic cancerJPRN-UMIN000040948Wakayama medical university49
Active, not recruiting
Phase 1
A prospective study of the safety and efficacy of the use of a Lipiodol Emulsion for the embolization of inflammatory hypervascularizations observed in patients with articular or abarticular pain in the knee - LipioJoint 1EUCTR2020-002206-10-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)22